Related Experiment Video
Updated: May 5, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Case Report: Recognition and management of SMARCA4-deficient renal cell carcinoma
Weibo Wang1,2, Shuiping Yin1,2, Dandan Xu3
1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Abstract:
SMARCA4-deficient tumors represent a highly aggressive subtype of malignancy defined by the loss of SMARCA4 expression, and are associated with rapid progression and poor prognosis. We report the first documented case of SMARCA4-deficient renal cell carcinoma (RCC) in an adult (pT3aN1M1, Stage IV), characterized by sarcomatoid and rhabdomyoblastic differentiation, aggressive clinical behavior, and resistance to standard systemic therapies. This case provides a comprehensive analysis of clinical, pathological, imaging, and genetic findings, offering insights to refine diagnostic, therapeutic, and preventive strategies for this rare malignancy.
Insights
We present the first adult case of aggressive SMARCA4-deficient renal cell carcinoma (RCC). This rare cancer shows resistance to therapies, highlighting the need for new strategies.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- SMARCA4-deficient tumors are aggressive, marked by rapid progression and poor prognosis.
- Loss of SMARCA4 expression defines this malignancy subtype.
